Two of the subgroups ( n = 8 ; n = 7 ) received E2 delivered at a rate of 0.05 mg/day and 0.1 mg/day , respectively , by transdermal patch , changed twice weekly ; the third subgroup received a placebo ( without E2 ) patch for 9 continuous months .
